HOWARU® Protect Early Life
Demand is growing for safe products with proven efficacy to support the immune health of infants. As part of the IFF Health premium ingredient range, HOWARU® Protect Early Life contains the probiotic strain HOWARU® L. rhamnosus HN001™ and is designed specifically for pregnant women and children (0 to 2 years)*.
It is proven to safely support the development of immune health in infants and children.
Download the handout to learn more.
- HOWARU® Lacticaseibacillus rhamnosus HN001™
Early Life DevelopmentAdvantages of HOWARU® Protect Early Life
- Supports immune health to help build infant’s natural defenses and continually supports immune health into childhood
- Provides increased levels of healthy bacteria in the intestinal tract of infants
SUPPORT THE DEVELOPMENT OF IMMUNE HEALTH IN YOUNG CHILDREN
A double-blind, randomized placebo-controlled clinical study was designed to test the efficacy of HOWARU® L. rhamnosus HN001™ on the prevalence of eczema and allergic sensitization. In total, 316 mothers and their infants were divided into placebo and HN001™ groups. Pregnant mothers were supplemented daily from 5 weeks pre-term to 6 months post-term if breastfeeding. Infants were supplemented daily from birth until 2 years old. The probiotic was administered in capsules to mothers and as powder, powder diluted in milk or sprinkled on top of the food to infants. At the age-points of 2, 4, 6 and 11 years, allergic disease-related outcomes (e.g., atopic sensitization) were determined by using clinical diagnosis and skin prick tests1-5.
Children in the HN001™ group had reduced allergic sensitization compared to placebo, which became statistically significant in the first 6 years of life and persisted through 11 years.
References: 1. Wickens et al., 2008; 2. Wickens et al., 2012; 3. Wickens et al., 2013; 4. Wickens et al. 2018a; 5. Wickens et al. 2018b.